AI Maverick Intel Secures Right of First Refusal on HEAL Group Healthcare Technology Assets

AI Maverick Intel Inc. (OTC: AIMV) has entered into a Right of First Refusal Agreement with HEAL Group Holdings Inc., granting the company the ability to review and match third-party offers for certain HEAL assets or business units under specified conditions. The agreement, effective February 11, 2026, provides AIMV with potential acquisition access across HEAL's portfolio of AI-driven healthcare technology and services operating in more than six countries. In exchange for this arrangement, AI Maverick Intel will issue 120,000,000 common shares to HEAL at a deemed price of $0.02 per share, representing total consideration of $2.4 million. The arrangement will remain in place for three years unless terminated earlier by mutual agreement.

This strategic agreement positions AI Maverick Intel to potentially acquire valuable healthcare technology assets that align with the company's focus on artificial intelligence and emerging technology-enabled industries. The right of first refusal gives AIMV a competitive advantage in evaluating and potentially acquiring specific HEAL Group assets before they become available to other interested parties. The healthcare technology sector represents a significant growth area, particularly as artificial intelligence applications continue to transform medical diagnostics, patient care, and healthcare administration systems worldwide.

The transaction structure, involving the issuance of shares rather than cash payment, preserves AI Maverick Intel's capital resources while providing HEAL Group with equity participation in the acquiring company. This arrangement creates alignment between the two entities regarding the future value of the potential acquisitions. The three-year term provides sufficient time for both companies to evaluate market conditions and specific asset performance before making acquisition decisions. The agreement covers multiple countries where HEAL Group operates, suggesting that AI Maverick Intel is positioning itself for potential international expansion through targeted acquisitions in the healthcare technology space.

For investors and industry observers, this agreement represents a strategic move by AI Maverick Intel to establish a foothold in the rapidly growing healthcare AI sector without immediate capital expenditure. The right of first refusal mechanism allows the company to conduct thorough due diligence on specific assets as they become available for potential acquisition. This approach minimizes risk while maintaining flexibility to pursue the most promising opportunities within HEAL Group's portfolio. The latest news and updates relating to AIMV are available in the company's newsroom at http://ibn.fm/AIMV. The full press release detailing this agreement can be viewed at https://ibn.fm/7LS0i.

The healthcare technology market continues to experience significant growth as organizations worldwide seek to improve patient outcomes through advanced data analytics and artificial intelligence applications. AI Maverick Intel's agreement with HEAL Group positions the company to potentially capitalize on this trend through selective acquisitions of proven technologies and established service platforms. The right of first refusal arrangement represents a strategic partnership approach that could accelerate AI Maverick Intel's entry into healthcare markets while providing HEAL Group with potential exit opportunities for specific assets. As artificial intelligence continues to transform healthcare delivery across multiple countries, agreements like this one highlight the growing convergence between AI technology companies and healthcare service providers seeking to leverage data-driven solutions for improved medical outcomes.